Mepha Ag

Melpha Ag

Ratiopharm Gmbh

Max Werner Scheiwe

Sven Winter

Dieter Swatschek

Thomas Villiger

Shitotomo Yamauchi

Christoph Grun

A pharmaceutically acceptable topical formulation for the treatment and/or prevention of skin ailments, more particularly of fibriotic nature such as fibriotic lesional tissues, contiguous warts, contact dermatitis, and keloids, and to assist the healing of burns after surgery, comprising as active ingredient a substituted pyridone of the formula: n-(R )-R -2-(1H)pyridone or a pharmaceutically acceptable salt or ester thereof, where R is selected from methyl, ethyl, propyl, carboxyl and a carboxymethyl or carboxyethyl ester group, R is selected from phenyl, methylphenyl, ethylphenyl, propylphenyl, and a carboxyphenyl or carboxyethylphenyl ester group, and n is 3, 4 or 5, together with an excipient, characterized in that the excipient comprises, one or more plasticisers, one or more antioxidants, one or more gel-forming agents and sufficient pH adjusting agent to bring the pH of the formulation to a value from 4 to 8. The preferred active ingredient is 5-methyl-1-phenyl-2-(1H)pyridone (Pirfenidone).

Topical formulation of alkyl-, phenyl-pyridone

The invention relates to a pharmaceutically active composition containing a substance which is active against malaria parasites and shows a high level of activity against multiresistant lines of,The inventive composition is characterized in that it contains the active agent artemisinine and/or a derivative of artemisinine in a carrier material which is inert with the active agent, in a pharmaceutically active quantity and in that the carrier material is essentially free of compounds with a hydrophilic-lipophilic balance between 7 and 9.9.

Pharmaceutically active composition containing artemisinine and/or derivative of artemisinine

Pharmaceutical pellet formulation

Growing community of inventors

Maulburg, Germany

Max Werner Scheiwe